Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BMS-986278 in idiopathic pulmonary fibrosis
jRCT2021230026Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Absolute change from baseline in forced vital capacity. Started Oct 2023; status: active, not recruiting.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2021230026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230026.